Reports FY22 revenue $700,000 vs $800,000 last year. "I am confident that the recently announced merger with Notable Labs Inc. provides the best path forward and will position the new enterprise to deliver both near and long-term value for shareholders of both companies and patients," said Prof. Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics. "The successful closing of the sale of VBL’s manufacturing facility for $7.1 million has provided an influx of non-dilutive capital that can be employed by the combined entity to advance its pipeline. I am impressed by the management team at Notable, who have an excellent track record developing successful pharmaceuticals, and the vision to create a leading clinical stage oncology company utilizing Notable’s Predictive Precision Medicine Platform."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on VBLT:
- VBL Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
- VBL Therapeutics close sales of manufacturing facility, assets for $7.1M
- VBL Therapeutics jumps 60% after announcing merger pact with Notable Labs
- VBL Therapeutics and Notable Labs Announce Definitive Merger Agreement
- VBL Therapeutics, Notable Labs enter definitive merger agreement
